OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Organization: Neurokine Therapeutics

2 Projects | 2 Researchers | $1,838,985 Invested

2017

Neurokine Therapeutics

Wayne Anderson, PhD

Phase 1 Studies and preparation of clinical phase 2 IND of MW150 : Novel Stress Kinase Inhibitor Candidate

  • Funding Amount: $1,688,985
  • Organization Type: Biotechnology/For Profit
  • Program: Clinical
  • Target: Neuroinflammation
  • Status: Closed

2016

Neurokine Therapeutics

D. Watterson, PhD

2016 Annual Goodes Prize for Excellence in Alzheimer's Drug Discovery: Catalyzing p38aMAPKI Drug Candidate, MW150, Into the Clinic

  • Funding Amount: $150,000
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Target: Neuroinflammation
  • Status: Closed